e-Drug3D

2012

LONAFARNIB

INN
LONAFARNIB

cas 193275-84-2

CLASS

VARIOUS
FARNESYL PROTEIN TRANSFERASE INHIBITOR
TREATMENT OF PROCESSING-DEFICIENT PROGEROID LAMINOPATHIES
TO REDUCE THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)

ROUTE (list)

ORAL

ATC code

A16AX20

PK parameters

Tmax 2 HOUR
VD 97.4 LITER
PPB 99 PERCENT
t1/2 5 HOUR

Target

TARGET FARNESYL PROTEIN TRANSFERASE

PDB
1O5M (STRUCTURE OF FPT BOUND TO THE INHIBITOR SCH66336)

Ligand code = 336 (link to the list of PDB complexes)

Download experimental 3D coordinates of 336 with added hydrogens

DrugCentral

Protein farnesyltransferase UNIPROT P49354 FNTA

Download SDF file

1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-

Formula:
C27H31Br2ClN4O2

Calculated chemical properties:

MW 638.81
NB_atoms 36
XLogP 5.91
PSA 63.229
NB_HD 2
NB_HA 6
fsp3 0.52
Lipinski(0=no;1=yes) 0

FDA
NDA 213969 (label) INN (LONAFARNIB) ZOKINVY (SENTYNL THERAPS INC) APPROVAL= AP YEAR= 2020 NEWMOLECULARENTITY